Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

39.70p
   
  • Change Today:
      0.20p
  • 52 Week High: 71.80
  • 52 Week Low: 34.50
  • Currency: UK Pounds
  • Shares Issued: 540.40m
  • Volume: 866,514
  • Market Cap: £214.54m
  • RiskGrade: 119

Alliance Pharma in 'good health' amid strong demand

By Josh White

Date: Wednesday 18 May 2022

LONDON (ShareCast) - (Sharecast News) - Alliance Pharma said in an update on Wednesday that its business was in "good health", with demand for its brand strong.
The AIM-traded firm, which was holding its annual general meeting, said the integration of ScarAway and the rights to Kelo-cote in the United States, acquired in March, was progressing "well".

Its board chair David Cook told shareholders that, in line with what it said at its full-year results in March, the company expected 2022 financial year performance to be weighted to the second half.

"[This is] due to our anticipated sales trajectory for Amberen and Nizoral, together with temporary disruption to our supply chain through Covid-related lockdowns in China, which is now beginning to ease," Cook said.

"We remain confident in our ability to deliver full year financial performance in line with market expectations."

Alliance said it would make further commentary on its first half performance in a trading update in July.

At 1429 BST, shares in Alliance Pharma were down 4.39% at 108.8p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 39.70p
Change Today 0.20p
% Change 0.51 %
52 Week High 71.80
52 Week Low 34.50
Volume 866,514
Shares Issued 540.40m
Market Cap £214.54m
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
78.84% above the market average78.84% above the market average78.84% above the market average78.84% above the market average78.84% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
67.54% below the market average67.54% below the market average67.54% below the market average67.54% below the market average67.54% below the market average
5.26% below the sector average5.26% below the sector average5.26% below the sector average5.26% below the sector average5.26% below the sector average
Income
10.21% below the market average10.21% below the market average10.21% below the market average10.21% below the market average10.21% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
89.09% below the market average89.09% below the market average89.09% below the market average89.09% below the market average89.09% below the market average
89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average89.19% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 66,726 @ 39.70p
16:35 196 @ 39.70p
16:35 738 @ 39.70p
16:35 62 @ 39.70p
16:35 661 @ 39.70p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin
Chair Camillo Pane

Top of Page